Observational studyAdvances in therapy2025

Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.

Gottfried Rudofsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.